Profile data is unavailable for this security.
About the company
EIKEN CHEMICAL CO., LTD. is a Japan-based company principally engaged in the manufacture and sale of test drugs. Through its subsidiaries, the Company involves in the processing, manufacture, purchase and sale of test agents. The products and services include microbial testing reagents, urine testing reagents, immunoserologic testing reagents, biochemical testing reagents and instrument food environment-related media.
- Revenue in JPY (TTM)39.52bn
- Net income in JPY2.33bn
- Incorporated1939
- Employees757.00
- LocationEiken Chemical Co LtdYamaguchi Bldg.7, 4-19-9, TaitoTAITO-KU 110-8408JapanJPN
- Phone+81 358463305
- Fax+81 358463476
- Websitehttps://www.eiken.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France Bed Holdings Co Ltd | 60.04bn | 3.21bn | 47.61bn | 1.78k | 14.02 | 1.11 | 5.48 | 0.7931 | 88.48 | 88.48 | 1,653.98 | 1,114.40 | 0.922 | 3.16 | 6.35 | 33,670,780.00 | 4.93 | 3.85 | 6.33 | 5.24 | 54.14 | 52.36 | 5.35 | 4.41 | 2.01 | -- | 0.2605 | 49.98 | 0.9782 | 2.70 | 15.99 | 3.81 | -1.01 | 9.30 |
| Medikit Co Ltd | 22.29bn | 3.03bn | 52.03bn | 966.00 | 14.74 | 0.9651 | 11.76 | 2.33 | 197.42 | 197.42 | 1,453.36 | 3,015.35 | 0.4192 | 3.58 | 4.29 | 23,074,350.00 | 5.69 | 5.75 | 6.40 | 6.31 | 38.75 | 40.05 | 13.58 | 14.08 | 4.77 | 4,935.02 | 0.00 | 38.88 | 1.13 | 3.38 | 7.15 | 3.56 | -0.6005 | 12.20 |
| CI Medical Co Ltd | 47.75bn | 1.43bn | 52.50bn | 473.00 | 36.63 | 2.57 | 15.65 | 1.10 | 28.66 | 28.66 | 955.00 | 408.47 | 1.16 | 4.28 | 14.43 | 100,945,000.00 | 3.55 | 10.83 | 7.19 | 15.65 | 25.73 | 27.73 | 3.06 | 6.06 | 0.524 | 200.36 | 0.4835 | 12.83 | 6.38 | 12.07 | -17.41 | 9.38 | 77.24 | 13.65 |
| TAUNS Laboratories Inc | 18.43bn | 5.77bn | 58.00bn | 271.00 | 9.96 | 4.21 | 8.99 | 3.15 | 57.74 | 57.74 | 184.35 | 136.67 | -- | -- | -- | 68,025,330.00 | -- | -- | -- | -- | 67.80 | -- | 31.32 | -- | 1.16 | 341.33 | 0.4111 | -- | 17.62 | -- | 90.26 | -- | -- | -- |
| Japan Eyewear Holdings Co Ltd | 15.43bn | 3.01bn | 63.80bn | 542.00 | 21.33 | 4.36 | 13.92 | 4.14 | 124.12 | 124.12 | 637.46 | 607.45 | 0.4565 | 2.19 | 13.25 | 28,459,410.00 | 8.90 | -- | 10.18 | -- | 78.21 | -- | 19.50 | -- | 1.18 | 10.04 | 0.5285 | -- | 26.17 | -- | 659.25 | -- | -- | -- |
| Shofu Inc | 37.52bn | 4.46bn | 74.83bn | 1.37k | 16.71 | 1.79 | 18.29 | 1.99 | 125.14 | 125.14 | 1,052.79 | 1,168.62 | 0.7951 | 1.44 | 9.49 | 27,406,870.00 | 9.48 | 6.15 | 10.62 | 7.00 | 59.71 | 57.76 | 11.92 | 8.12 | 2.89 | -- | 0.0048 | 31.84 | 10.74 | 7.08 | 16.59 | 24.93 | 5.03 | 21.94 |
| Intermestic Inc | -100.00bn | -100.00bn | 77.63bn | 1.84k | -- | 7.28 | -- | -- | -- | -- | -- | 348.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.10 | -- | 0.494 | -- | 11.12 | -- | 102.26 | -- | -- | -- |
| Nagaileben Co., Ltd. | 16.41bn | 2.82bn | 79.48bn | 511.00 | 25.04 | 1.64 | 33.20 | 4.84 | 88.80 | 88.80 | 516.26 | 1,355.91 | 0.3488 | 1.48 | 3.29 | -- | 6.00 | 7.32 | 6.43 | 7.92 | 42.83 | 44.58 | 17.19 | 19.71 | 10.20 | -- | -- | 57.20 | -4.48 | -0.4484 | -12.53 | -3.91 | -6.53 | 0.00 |
| Eiken Chemical Co Ltd | 39.52bn | 2.33bn | 83.60bn | 757.00 | 33.51 | 1.62 | 25.63 | 2.12 | 64.72 | 64.72 | 1,103.44 | 1,339.12 | 0.6099 | 2.74 | 3.30 | 52,202,110.00 | 3.59 | 8.01 | 4.41 | 10.14 | 41.23 | 45.92 | 5.88 | 11.50 | 2.13 | -- | 0.0608 | 35.45 | -7.44 | 2.29 | -54.08 | -5.24 | 11.66 | 11.20 |
| Japan Lifeline Co., Ltd. | 54.24bn | 7.92bn | 97.65bn | 1.22k | 11.93 | 1.65 | 10.20 | 1.80 | 108.04 | 108.04 | 738.09 | 779.23 | 0.7759 | 1.41 | 4.07 | 44,602,800.00 | 11.33 | 8.63 | 14.02 | 10.88 | 60.32 | 57.28 | 14.60 | 12.28 | 1.62 | -- | 0.0885 | 48.80 | -0.7073 | 2.45 | 9.06 | -0.5446 | 5.40 | 7.69 |
| HOGY MEDICAL CO., LTD. | 29.29bn | 2.08bn | 102.09bn | 1.41k | 52.92 | 1.29 | 15.02 | 3.49 | 85.61 | 85.61 | 1,278.04 | 3,515.34 | 0.2912 | 1.99 | 2.33 | 20,801,850.00 | 2.06 | 4.24 | 2.27 | 4.67 | 32.53 | 39.76 | 7.09 | 11.58 | 3.80 | -- | 0.1621 | 45.68 | 0.3053 | 1.30 | -35.03 | -14.24 | 7.94 | 4.56 |
Data as of Nov 15 2024. Currency figures normalised to Eiken Chemical Co Ltd's reporting currency: Japanese Yen JPY
36.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dalton Investments, Inc.as of 18 Oct 2024 | 4.18m | 10.85% |
| Asset Value Investors Ltd.as of 05 Mar 2024 | 2.01m | 5.21% |
| Nomura Asset Management Co., Ltd.as of 03 Oct 2024 | 1.12m | 2.90% |
| Nikko Asset Management Co., Ltd.as of 30 Nov 2023 | 1.10m | 2.86% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 1.08m | 2.79% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.07m | 2.78% |
| Highclere International Investors LLPas of 31 Mar 2024 | 1.06m | 2.75% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 30 Nov 2023 | 1.05m | 2.73% |
| MFS International Singapore Pte Ltd.as of 30 Sep 2024 | 949.70k | 2.46% |
| Daiwa Asset Management Co. Ltd.as of 30 Sep 2024 | 490.60k | 1.27% |
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
